Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Leukemia Inhibitory Factor: A Main Controller of Breast Cancer Publisher Pubmed



Vaziri N1 ; Shariati L2, 3 ; Javanmard SH4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Cell and Molecular Biology, School of Biology, Kish International Campus, University of Tehran, Kish, Iran
  2. 2. Department of Biomaterials, Tissue Engineering and Nanotechnology, School of Advanced Medical Technologies, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Cancer Prevention Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  4. 4. Applied Physiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Journal of Biosciences Published:2020


Abstract

Breast cancer is the second leading cause of cancer-related death among females, worldwide. The cytokines are proteins that have a significant role in the development of tumor growth. Leukemia inhibitory factor (LIF) of the interleukin-6 cytokines superfamily plays a significant role, by the modulation of many signaling pathways. This study summarizes some current works in breast cancer, in which LIF intervention is being discussed. LIF promotes tumorigenesis, invasion, migration of breast cancer cells in vitro, metastasis of breast cancer in vivo, epithelial-mesenchymal transition, and mediates pro-invasive activation of stromal fibroblast. LIF contributes to inducing growth, tumorigenesis, and metastasis of breast cancer and is a significant biomarker for breast tumors and can be a therapeutic target for clinical intervention. © 2020, Indian Academy of Sciences.